Galapagos NV (NASDAQ:GLPG) Receives $25.33 Average Price Target from Analysts

Galapagos NV (NASDAQ:GLPG - Get Free Report) has earned a consensus recommendation of "Reduce" from the eight ratings firms that are presently covering the stock, MarketBeat Ratings reports. Four investment analysts have rated the stock with a sell rating and four have given a hold rating to the company. The average 1 year price objective among brokers that have updated their coverage on the stock in the last year is $25.33.

Separately, Wall Street Zen cut shares of Galapagos from a "hold" rating to a "sell" rating in a research note on Friday, April 25th.

Galapagos Price Performance

Galapagos stock traded down $0.11 during trading on Thursday, reaching $28.76. The company had a trading volume of 322,184 shares, compared to its average volume of 245,427. The firm's 50-day simple moving average is $26.82 and its 200 day simple moving average is $26.08. Galapagos has a 1-year low of $22.36 and a 1-year high of $31.23.

Galapagos (NASDAQ:GLPG - Get Free Report) last announced its earnings results on Wednesday, April 23rd. The biotechnology company reported ($2.47) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.23) by ($2.24). The business had revenue of $97.33 million for the quarter, compared to the consensus estimate of $72.22 million. As a group, equities research analysts anticipate that Galapagos will post -1.6 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of the stock. QRG Capital Management Inc. raised its holdings in Galapagos by 21.7% in the 4th quarter. QRG Capital Management Inc. now owns 10,455 shares of the biotechnology company's stock valued at $288,000 after buying an additional 1,866 shares during the period. American Century Companies Inc. raised its holdings in Galapagos by 5.9% in the 4th quarter. American Century Companies Inc. now owns 25,852 shares of the biotechnology company's stock valued at $711,000 after buying an additional 1,431 shares during the period. Norges Bank purchased a new stake in Galapagos in the 4th quarter valued at about $3,300,000. Finepoint Capital LP raised its holdings in Galapagos by 21.0% in the 4th quarter. Finepoint Capital LP now owns 674,762 shares of the biotechnology company's stock valued at $18,556,000 after buying an additional 117,000 shares during the period. Finally, Renaissance Technologies LLC raised its holdings in Galapagos by 1.5% in the 4th quarter. Renaissance Technologies LLC now owns 296,100 shares of the biotechnology company's stock valued at $8,143,000 after buying an additional 4,421 shares during the period. Hedge funds and other institutional investors own 32.46% of the company's stock.

Galapagos Company Profile

Galapagos NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe. The company's pipeline products comprise GLPG3667 that has completed phase 1b trial; GLPG5101, a CD19 CAR-T product candidate manufactured at point-of-care, currently in Phase1/2 trial in relapsed/refractory non-hodgkin lymphoma; GLPG5201, a CD19 CAR-T product candidates manufactured at point-of-care, currently in phase 1/2 trial in replapsed/refractory chronic lymphocytic leukemia; and GLPG5301, a BCMA CAR-T product candidate manufactured at point-of-care, currently in phase 1/2 in relapsed/refractory multiple myeloma.